Search
PICOBOO (The Platform Trial In COVID-19 Priming and BOOsting) Study and NOVAVAX COVID-19/Influenza Combined Vaccine Study
Latest news & events at the Wesfarmers Centre of Vaccines & Infectious Diseases.
IIC Perth 2019 Faculty Testimonials Contact us I liked the breadth available in the course: both local and international, and very specialised areas
News & Events
Respiratory SymposiumMore information For more information regarding the Respiratory Symposium, please contact Dr Hannah Moore.
Find out more about the scholarship opportunities at the Wesfarmers Centre, including Training Scholarships and Higher Degree by Research Scholarships.
Wesfarmers Centre of Vaccines & Infectious Diseases resources
ORIGINS is the largest study of its kind in Australia, following 10,000 children, from their time in the womb, over a decade to improve child and adult health.
Research
Host-dependent resistance of Group A Streptococcus to sulfamethoxazole mediated by a horizontally-acquired reduced folate transporterDescribed antimicrobial resistance mechanisms enable bacteria to avoid the direct effects of antibiotics and can be monitored by in vitro susceptibility testing and genetic methods. Here we describe a mechanism of sulfamethoxazole resistance that requires a host metabolite for activity.
Research
Penicillin G concentrations required for prophylaxis against Group A Streptococcus infection evaluated using a hollow fibre model and mathematical modellingAcute rheumatic fever (ARF), an autoimmune reaction to Group A Streptococcus (Streptococcus pyogenes; Strep A) infection, can cause rheumatic heart disease (RHD). New formulations of long-acting penicillins are being developed for secondary prophylaxis of ARF and RHD.
Research
Antifungal use in children with acute leukaemia: state of current evidence and directions for future researchInvasive fungal disease (IFD) remains a common and serious complication in children treated for leukaemia. Antifungal prescription in children with leukaemia presents unique challenges, particularly due to variation in IFD risk between and within leukaemia treatment protocols, drug toxicities and interactions between antifungals and chemotherapeutic agents.